English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Discovery of oligosaccharide antigens for semi-synthetic glycoconjugate vaccine leads against Streptococcus suis serotypes 2, 3, 9 and 14

MPS-Authors
/persons/resource/persons260135

Zhang,  Shuo
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons219908

Sella,  Mauro
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons242817

Sianturi,  Julinton
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons251980

Priegue,  Patricia       
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons244010

Shen,  Dacheng
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121849

Seeberger,  Peter H.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Article.pdf
(Publisher version), 5MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Zhang, S., Sella, M., Sianturi, J., Priegue, P., Shen, D., & Seeberger, P. H. (2021). Discovery of oligosaccharide antigens for semi-synthetic glycoconjugate vaccine leads against Streptococcus suis serotypes 2, 3, 9 and 14. Angewandte Chemie International Edition, 60(26), 14679-14692. doi:10.1002/anie.202103990.


Cite as: https://hdl.handle.net/21.11116/0000-0008-5D45-3
Abstract
Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotype 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi-synthetic S. suis serotype 2 and 9 glycoconjugate veterinary vaccines were identified in this way.